Montreal, Canada, March 3, 2016 – Moleculomics, a UK university spin-out company offering powerful high-throughput prediction of small molecule – protein interactions using cutting-edge in silico modelling and screening tools, is pleased to announce the official opening of its North American sales and support office within the NEOMED Institute in Laval,
We recently presented a poster at the 2nd Annual Drug Discovery USA Congress, 29-30 October 2015, Boston, USA. You can view the poster below and you can then use the left and right arrow keys on your keyboard to progress through the presentation and view the poster.
Alternatively, you may download the poster in pdf format using the following link
Moleculomics, a company specializing in molecular research for the pharmaceutical, defence and biotech industries, announced the opening of its first North American facility in Greater Montréal.
Founded just four years ago in Wales, the U.K.-based company develops computing biosimulation (in silico modelling) tools and data platforms to improve knowledge of molecular interactions in new drugs and chemical compounds.
Leading research featuring Moleculomics CEO Dr Jonathan Mullins has recently been published. The Swansea University press release explains more below…
To see the article in it’s original form, please see here
An international team of researchers have created unusually intelligent mice by altering a single gene, but found the mice were also less likely to feel anxiety or recall fear.
Moleculomics, a spin out of Swansea University have recently been awarded prestigious funding from the NC3Rs through a CRACK-IT challenge to develop technologies which will identify off-target Molecular Initiation Events (MIEs) and link these to associated Adverse Outcome Pathways (AOPs) through the application of software technology developed at the Institute of Life Science over the past 10 years.
Moleculomics Ltd is a Swansea-based SME established by Jonathan Mullins, an Associate Professor at Swansea University’s Institute of Life Sciences, in order to ensure that the outputs of his academic research are used to benefit society and with the aim of creating new wealth and jobs in the Welsh digital life science sector.
Platform for success
New in silico platform for antimicrobial development to meet the UK’s defence and security needs
Moleculomics, based in Swansea, in South Wales, has collaborated with the Defence Science and Technology Laboratory (Dstl) to produce an innovative new platform to assist in the development of novel antimicrobials.
This collaboration has led to the computational prediction of structures of entire bacterial genomes and the identification of homologous antimicrobial targets across a number of different organisms.
A GROWING Swansea-based drug research and product company which is about to expand overseas has taken part in a national event to discuss its work.
Moleculomics, which employs eight people, is based at Swansea University and is set to launch a subsidiary company in Canada later this year.
A representative from the business,
Moleculomics is pleased to announce it has received the CompTIA IT Business Trustmark™, a respected industry credential that signifies its commitment to sound business practices and quality service.
“Earning this credential identifies Moleculomics as a business that meets or exceeds the best business practices the IT industry has to offer,” said John McGlinchey,
Milestone training figure reached as Swansea pharmaceutical firm takes on four Academy graduates
We are delighted to announce that we have now provided supercomputing training to over 1,500 users. Our Skills Academy, which delivers a variety of courses and workshops aimed at building skills in high performance computing (HPC), has seen student numbers more than double in the past 12 months.